ADDIT-CE NeuroConnect Meetup - Catching up on the atmosphere!
Catching up on the atmosphere!
A few snapshots from the ADDIT-CE NeuroConnect Meetup (27 Nov 2025, Brno)—full of ideas, connections, and inspiring conversations.
22 pitch presenters. One inspiring community.
From innovative research approaches to new collaborative opportunities in Alzheimer’s and neurodegenerative disease research, the pitches sparked engaging discussions and meaningful exchanges.
Thank you to all presenters for your energy, openness, and commitment to advancing research, care, and innovation.
🤝Thank you to our project partner for the great cooperation BioVendor, Masaryk University, and JIC.
The project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No101087124.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
